
“I was keen to go on a clinical trial. I wanted to try new cancer treatments and hopefully help future generations.”
Please note - this trial is no longer recruiting patients. We hope to add results when they are available.
This study is looking at pertuzumab and trastuzumab (Herceptin) with a taxane chemotherapy drug for breast cancer that is HER2 positive. The taxane chemotherapy drug could be one of the following
This study is open to women and men whose breast cancer has spread into surrounding tissue () or to another part of their body (secondary breast cancer).
Doctors can treat breast cancer that has spread or come back and is HER2 positive with trastuzumab and a taxane chemotherapy drug. This combination works but they are always looking for ways to improve treatment.
Pertuzumab is a type of biological therapy called a monoclonal antibody. Monoclonal antibodies seek out cancer cells by looking for a particular protein.
We know from research that the combination of pertuzumab and trastuzumab with docetaxel works for HER2 positive advanced breast cancer.
The aims of this study are to find out
You may be able to enter this study if
You cannot enter this study if
This is an international phase 3 study. It will recruit 1,500 people from different countries around the world.
Everyone taking part will have pertuzumab and trastuzumab alongside a taxane chemotherapy drug. The taxane drug could be docetaxel, paclitaxel or nab-paclitaxel. You have all of these as a drip into a vein. You may have them as a drip into a central line, PICC line or portacath. You have them every 3 weeks. You can continue treatment as long as it is helping you and the side effects aren’t too bad.
For the women who take part in this study, the team will ask you to fill out a questionnaire before you start treatment and then every 9 weeks during treatment, a month after treatment and then every 3 months. The questionnaire will ask about side effects and how you’ve been feeling. This is called a quality of life study.
You see the doctor to have some tests before taking part in this study. These tests include
During treatment you see the doctor every 3 weeks for a physical examination and blood tests. Every 9 weeks you have a
After treatment you see the doctor every 3 months. If your cancer didn’t get worse during treatment you will also have a scan.
The most common side effects of pertuzumab and trastuzumab are
The most common side effects of paclitaxel, nab-paclitaxel and docetaxel drugs are
Your doctor will talk to you about the possible side effects before you agree to take part in this trial.
We have more information about trastuzumab, pertuzumab, docetaxel, paclitaxel and nab-paclitaxel in our cancer drugs section.
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Dr David Miles
Experimental Cancer Medicine Centre (ECMC)
National Institute for Health Research Cancer Research Network (NCRN)
Roche
Freephone 0808 800 4040
“I was keen to go on a clinical trial. I wanted to try new cancer treatments and hopefully help future generations.”